Corticosterone 18-monooxygenase explained
| corticosterone 18-monooxygenase |
| Ec Number: | 1.14.15.5 |
| Cas Number: | 37256-75-0 |
| Go Code: | 0047783 |
In enzymology, a corticosterone 18-monooxygenase is an enzyme that catalyzes the chemical reaction
corticosterone + reduced adrenal ferredoxin + O2
18-hydroxycorticosterone + oxidized adrenal ferredoxin + H
2O
[1] The 3 substrates of this enzyme are corticosterone, reduced adrenal ferredoxin, and O2, whereas its 3 products are 18-hydroxycorticosterone, oxidized adrenal ferredoxin, and H2O.[2]
This enzyme belongs to the family of oxidoreductases, specifically those acting on paired donors, with O2 as oxidant and incorporation or reduction of oxygen. The oxygen incorporated need not be derived from O2 with reduced iron-sulfur protein as one donor, and incorporation of one atom of oxygen into the other donor.[3] [4] The systematic name of this enzyme class is corticosterone,reduced-adrenal-ferredoxin:oxygen oxidoreductase (18-hydroxylating). Other names in common use include corticosterone 18-hydroxylase, and corticosterone methyl oxidase. This enzyme participates in c21-steroid hormone metabolism.[5]
Notes and References
- Web site: ENZYME - 1.14.15.5 corticosterone 18-monooxygenase . live . https://web.archive.org/web/20220820192459/https://enzyme.expasy.org/EC/1.14.15.5 . 2022-08-20 . 2022-08-20 . enzyme.expasy.org.
- Web site: PhytoMine: GOTerm GO:0047783 corticosterone 18-monooxygenase activity GO . live . https://web.archive.org/web/20220820192303/https://phytozome-next.jgi.doe.gov/phytomine/report.do?id=1841678195 . 2022-08-20 . 2022-08-20 . phytozome-next.jgi.doe.gov.
- McDonald A . 2019 . The Enzyme List Class 1 — Oxidoreductases . live . . . 1 . 1 . 759 . https://web.archive.org/web/20220305142108/https://www.enzyme-database.org/downloads/ec1.pdf . 2022-03-05 . 2022-08-20 . Trinity College Dublin.
- Pivonello R, Fleseriu M, Newell-Price J, Bertagna X, Findling J, Shimatsu A, Gu F, Auchus R, Leelawattana R, Lee EJ, Kim JH, Lacroix A, Laplanche A, O'Connell P, Tauchmanova L, Pedroncelli AM, Biller BM . 6 . Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase . The Lancet. Diabetes & Endocrinology . 8 . 9 . 748–761 . September 2020 . 32730798 . 10.1016/S2213-8587(20)30240-0 . 220892722 .
- Yanagibashi K, Shackleton CH, Hall PF . Conversion of 11-deoxycorticosterone and corticosterone to aldosterone by cytochrome P-450 11 beta-/18-hydroxylase from porcine adrenal . en-US . Journal of Steroid Biochemistry . 29 . 6 . 665–675 . June 1988 . 3386233 . 10.1016/0022-4731(88)90167-7 .
